Skip to content
Homepage
Author:
Vaxcyte, Inc.
Posted Date:
August 5, 2026
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
Vaxcyte, Inc.
August 5, 2026
Vaxcyte to Participate in Upcoming Investor Conferences
Vaxcyte, Inc.
July 8, 2026
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
Vaxcyte, Inc.
June 2, 2026
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Vaxcyte, Inc.
May 8, 2026
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Vaxcyte, Inc.
April 7, 2026
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte, Inc.
March 23, 2026
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Vaxcyte, Inc.
March 18, 2026
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vaxcyte, Inc.
February 25, 2026
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Vaxcyte, Inc.
February 12, 2026
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Vaxcyte, Inc.
February 10, 2026
1
2
Next
